Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 22Myelodysplastic Syndromes 2Targeted Therapy 1Recurrence 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Infections 1Hematologic Neoplasms 1Disease 1Carcinoma, Non-Small-Cell Lung 1Blast Crisis 1

Interventions

fludarabine 9Cytarabine 9venetoclax 5fludarabine phosphate 5Cyclophosphamide 5Busulfan 5thymoglobulin 4Tacrolimus 4Sirolimus 4Mycophenolic Acid 4Methotrexate 4Azacitidine 4aldesleukin 3Whole-Body Irradiation 3Interleukin-2 3Antilymphocyte Serum 3asciminib 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Dasatinib 2Cyclosporine 2Bone Marrow Transplantation 2Blood Specimen Collection 2Behavior Therapy 2zileuton 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid × gilteritinib × Clear all
NCT06235801 2026-06-02

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡